Background-Hypertrophic cardiomyopathy is the most common type of cardiomyopathy, but many patients lack sarcomeric/myofilament mutations. We studied whether cardio-specific α-galactosidase A gene variants are misinterpreted as hypertrophic cardiomyopathy because of the lack of extracardiac organ involvement. Methods and Results-All subjects who tested positive for the N215S genotype (n=26, 13 females, mean age 49±17 [range, 14-74] ), and diastolic function mildly abnormal. Cardiac magnetic resonance imaging revealed replacement fibrosis in loco typico (18/26, 69%), particularly in subjects >50 years. Elderly subjects had advanced heart failure, and 6 (23%) were suggested for implantable cardioverter-defibrillator therapy. Leukocyte α-galactosidase A enzyme activity was mildly reduced in 19 subjects and lyso-globotriaosylceramide slightly elevated (median, 4.9; interquartile range, 1.3-9.1 ng/mL). Neurological and renal impairments (serum creatinine, 0.87±0.20; median, 0.80; interquartile range, 0.70-1.01 mg/dL; glomerular filtration rate, 102±23; median, 106; interquartile range, 84-113 mL/min) were discreet. Only 2 subjects developed clinically relevant proteinuria. Conclusions-α-Galactosidase A genotype N215S does not lead to the development of a classical Fabry phenotype but induces a specific cardiac variant of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy. The lack of prominent noncardiac impairment leads to a significant delay in diagnosis and Fabry-specific therapy. (Circ Cardiovasc Genet.
H ereditary cardiomyopathies are a leading cause of both progressive heart failure and sudden cardiac death in patients presenting with left ventricular (LV) hypertrophy (LVH) of unknown origin. The CARDIA study (Coronary Artery Risk Development in Young Adults) investigated the prevalence of hypertrophic cardiomyopathy (HCM) in the general population, reporting a prevalence of 1:500. 1 Newer studies have indicated even higher incidences of ≤1:200, suggesting that HCM is the most common heredity-determined cardiomyopathy, affecting both sex and all races. 2, 3 HCM has also been discussed as a rare but relevant cause of sudden cardiac death in young athletes, with a clinical diagnosis based on a global or segmental LV wall thickness ≥15 mm after alternative causes have been ruled out. 4, 5 The pathology of HCM has been described related to several mutations in at least 11 sarcomeric or myofilament-related genes. 3, 6 However, pathogenic mutations are only found in 60% to 70% of all patients clinically suspected of having HCM, whereas the genetic background and pathophysiological mechanisms underlying these cardiomyopathies remain unknown in many cases. The variety of heterogeneous genotypes and phenotypes has been N215S Cardiomyopathy hypothesized to reflect allele-specific expression and partial silencing of mutant transcripts, potentially serving as a model for future therapeutic targets. 7 However, mutations in nonsarcomeric genes may be another currently underestimated cause of the development of phenotypic HCM.
Pathogenic α-galactosidase A (enzyme commission number: 3.2.1.22) encoding gene (GLA) mutations have been described as a rare differential diagnosis in subjects suspected of HCM. 8, 9 As a progressive multisystemic disorder, organ manifestations and symptoms may vary greatly in Fabry disease (OMIM 301500) depending on modifying factors, such as the individual's genotype, age, and sex. 10 Though involvement of the kidneys, peripheral nerves, and brain have historically been described as the predominant pathologies, increasing evidence indicates clinically relevant cardiac organ involvement in several affected patients. 11, 12 Recent studies investigating the impact of the specific genetic background on the development of clinical manifestations in Fabry disease described a set of late-onset variants, 13, 14 including the GLA genotype N215S. However, no comprehensive data have been published characterizing patients with this genotype relative to the classical Fabry phenotype. Thus, we investigated the phenotype-specific characteristics of 26 subjects from 12 families carrying the N215S genotype who were initially misdiagnosed with genetically determined HCM.
Methods

Subjects and Mutation Analysis
All index subjects were initially referred by external clinicians with a suspicion of genetically determined HCM, triggering further investigations, including biopsy. Additional subjects were identified by family screening. All subjects were referred to our reference center of excellence for further clinical evaluation and therapy planning. Genetic analysis (Molecular Genetics and Metabolism Laboratory, Munich, Germany and Centogene AG, Rostock, Germany) after biopsy analyses revealed the GLA mutation c.644A>G (p.Asn215Ser, abbreviated N215S) on exon 5. We identified 26 subjects (13 females and 12 families) positive for the specific N215S genotype at mean±SD 49±17 (range, 14-74) years of age (Table 1) . Index subjects (n=10, 58±8 years) were older at the time of diagnosis than the subjects identified by family screening (n=16, 44±19 
years).
After the baseline visit, all subjects were recommended for annual follow-up visits, which have been performed in 14 subjects. Genotype-specific characteristics were investigated by comparing subjects with the N215S genotype to age-and sex-matched control subjects tested positive for GLA mutations known to be associated with classical Fabry phenotypes as reported previously. 15 The study was performed in accordance with the Declaration of Helsinki and approved by the local Ethics Committee of the Medical Faculty of the University of Würzburg, Germany. All study participants provided written informed consent for scientific analysis and publication of their biomaterial and clinical data.
Family History, Clinical, and Health-Related Quality of Life Assessments
Detailed family histories were acquired with a focus on all potential Fabry-associated diagnoses, life expectancy, and presumable reasons for death. Attention was paid to reports of typical complications, such as sudden cardiac death, heart failure, myocardial infarction, cardiac device therapy, early-onset or repetitive cerebral stroke, pain of unknown origin, reduced sweating capacity, chronic kidney disease, and history of or demand for organ transplantation. Identified subjects underwent comprehensive assessments of cardiac and noncardiac signs, symptoms, and organ involvement as described previously. 16 In addition, health-related quality of life was studied using the SF-36 survey.
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Renal Function and Biomarker Analysis
Glomerular filtration rate was measured by 99-Technetium-DiethyleneTriamine-Pentaacetic Acid clearance and estimated for long-term trend analyses according to the Modification of Diet in Renal Disease formula. α-gal A indicates α-galactosidase A enzyme activity; BMI, body mass index; f, female; hs-TnT, high-sensitive troponin T; IQR, interquartile range; m, male; NA, not available; NT-proBNP, N-terminal pro-brain natriuretic peptide. Reference values: α-gal A, 0.4-1.0 nmol/min per mg protein unless otherwise indicated by footnotes; hs-TnT, <14 pg/mL; Lyso-Gb3, <0.9 ng/mL; NT-proBNP (age-dependent), <125 pg/mL. *Reference 0.36-0.84 MU/mg. †Reference >2.0 μmol/L per h. ‡Reference >33 nmol MU/mg. N215S Cardiomyopathy Serum creatinine (reference, 0-0.95 mg/dL) and the extent of albuminuria expressed as the urinary albumin-to-creatinine ratio (UACR; reference, <30 mg/g creatinine) were calculated. The cardiac biomarkers NT-proBNP (N-terminal pro-brain natriuretic peptide; reference, <125 pg/mL) and cardiac hs-TnT (high-sensitive troponin T; reference, <14 pg/mL) were measured as indicators of the extent and progression of cardiac organ involvement. 18 Serum lyso-globotriaosylceramide (Gb3; reference, <0.9 ng/mL) and the leukocyte α-galactosidase A enzyme activity (reference, 0.4-1.0 nmol/min per mg protein) were determined by Centogene (Rostock, Germany) as Fabry-specific biomarkers reflecting disease severity and temporal progression.
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Cardiac Imaging and Functional Diagnostics
All cardiac imaging modalities were performed in accordance with state-of-the-art guideline recommendations as described elsewhere. 16 The modalities included 2-dimensional echocardiography using a Vivid 7 3.5 MHz Ultrasound (GE, Horten, Norway), 2-dimensional speckle tracking for off-line quantification of myocardial deformation values using EchoPAC (GE Vingmed Ultrasound AS), 16, 22, 23 and morphological and late gadolinium enhancement cardiac magnetic resonance imaging (MRI) on a 3-Tesla full-body scanner (MAGNETOM Trio, Siemens Healthcare, Erlangen, Germany). Subjects with implanted cardiac devices were excluded from MRI.
Histopathological Analysis of Cardiac and Renal Biopsies
Endomyocardial biopsies (EMBs) were obtained from subjects No. 15 and Nos. 20 to 22. For light microscopy, myocardial tissue was fixed in buffered formalin, embedded in paraffin, sectioned, and stained with Masson's trichrome. For electron microscopy, specimens were fixed in glutaraldehyde and processed as described previously. 24 Ultrasound-guided renal biopsies were obtained from subjects No. 9, No. 14, and No. 24 for stratification of Gb3 accumulation, the gold standard indicator of kidney organ involvement. The samples were analyzed by standard light microscopy, immunohistology, and electron microscopy.
Central and Peripheral Nervous System Diagnostics
To assess the potential involvement of the central nervous system, brain MRI was performed on a 3-Tesla whole-body magnetic resonance scanner (MAGNETOM Trio/SKYRA; Siemens Healthcare, Erlangen, Germany) as described previously. 16 In addition, all subjects underwent nerve conduction studies of the right sural nerve using surface electrodes and antidromic recording. 25 The results were compared with age-matched normative values from our laboratory. Quantitative sensory testing was performed in all subjects using a calibrated device (Somedic, Hörby, Sweden). 26 The vibration detection threshold was also determined as large fiber function and compared with published reference values. 27 To investigate the involvement of small nerve fibers, skin punch biopsies (Stiefel GmbH, Offenbach, Germany) were obtained from the distal leg and back as reported previously. 16, 28 Biopsy samples were fixed in 4% paraformaldehyde at 4°C for 2 hours and intraepidermal nerve fibers assessed on 50-μm cryosections. The sections were immunoreacted with antibodies against protein-gene product 9.5 (Ultraclone, UK; 1:800) as a panaxonal marker. The secondary antibody was goat anti-rabbit IgG labeled with cyanine 3.18 fluorescent probe (Cy3, 1:100; Amersham, USA). Intraepidermal nerve fiber density was quantified according to published counting rules.
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Statistical Analysis
Continuous data are presented as mean±SD or median (interquartile range [IQR] ). Categorical variables are presented as numbers and percentages. Differences in normally distributed continuous data between baseline and follow-up among subjects with the N215S genotype and controls were compared using linear mixed models, with the fixed factor of study groups nested within the random factor of family ID, controlling for within-family relatedness. Non-normally distributed variables were normalized prior to analysis using natural logarithm. Differences in categorical variables between baseline and follow-up among 2 patient groups were compared using generalized estimating equations and corrected for within-family relatedness. Multiple linear regression analysis was used to assess the association between dependent variables (ie, echocardiographic data, late gadolinium enhancement, NT-proBNP, and 99-TechnetiumDiethylene-Triamine-Pentaacetic Acid clearance) and age after controlling for family relatedness. Differences in strain and strain rate among basal, mid, and apical levels were compared using 1-way analysis of variance followed by Tukey's multiple comparison post hoc tests. Significance is indicated by P<0.05. Data were analyzed using IBM SPSS Statistics, version 23.0 (SPSS Inc., Chicago, IL).
Results
Resting blood pressure and heart rate were in physiological ranges in almost all subjects. The mean systolic blood pressure of the 26 subjects was 132±16 (range, 105-175) mm Hg, diastolic blood pressure 80±10 (60-100) mm Hg, and heart rate 68±13 (46-96) beats per minute. The α-galactosidase A enzyme activity was reduced in 19 (73%) subjects, whereas lyso-Gb3 was mildly elevated (4.9 ng/mL; IQR, 1.3-9.1; reference, ≤0.9). In one subject, enzyme replacement therapy had been initiated before the first visit at our center. In 12 of the other 25 subjects (48%; 10 men and 2 women), Fabryspecific therapy was started on recommendation onsite (n=4 agalsidase alpha, n=5 agalsidase beta, and n=3 migalastat). Among the 26 subjects, 8 (31%) received β-blockers, 9 (35%) angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, 1 (4%) calcium antagonists, and 4 (15%) acetylsalicylic acid or oral anticoagulation therapy. None of the subjects received diuretics. Disease progression and the temporal course were comprehensively assessed in 14 (54%) subjects with a mean follow-up of 58±49 (range, 12-140) months.
Identifying Index Subjects
After the identification of 10 index subjects (Nos. 9, 11, 14-16, 18, 20-22, and 24), family screenings revealed another 16 related gene carriers who attended our center and were consecutively included in the study. We also identified another 29 genetically related subjects who must have been N215S gene carriers based on the rules of genetic penetrance but had died prior to index identification and did not undergo genetic testing.
Four index subjects (Nos. 15 and 20-22) were identified by EMB performed for secondary evaluation of anticipated HCM in an effort to elucidate the underlying causes of cardiomyopathy of yet unknown origin (Figure 1 ). Subject No. 15 had been misdiagnosed for nonobstructive HCM in his mid-30s, presenting with advanced LVH at the routine check-up performed during preparation for elective orthopedic surgery. His family pedigree revealed several relatives at risk and a remarkable number of premature sudden cardiac deaths (Figure 2 ). Prior to the diagnosis of Fabry disease, all family members were referred to regular clinical follow-up for anticipated HCM with no specific therapy. At 54 years of age, subject No. 15 suffered from cardiac arrest. After successful cardiopulmonary resuscitation, he received a secondary prophylactic implantable cardioverter-defibrillator. In addition, an EMB was performed, leading to the incidental finding of vacuoles, hinting at a storage disorder. Subject No. 20 was suspected to have apical HCM and was diagnosed with N215S after EMB indicated a storage disorder. In subject No. 21, myocardial infarction was suspected because of the combination of angina pectoris and elevated levels of hs-TnT. The subject underwent angiographic examination followed by EMB. Subject No. 22 was identified by routine check-up revealing LVH of unknown origin at 63 years of age. Three index subjects (Nos. 9, 14, and 24) were identified by renal glomerular biopsy performed because of the presence of proteinuria of unknown origin. In subject No. 24, family analysis was not feasible. In subject Nos. 16 and 18, LVH of unknown origin raised suspicion of HCM, triggering genetic analysis for both HCM and Fabry disease. Subject No. 17 was identified by family screening after Fabry disease was diagnosed in his 73-year-old first-degree cousin because of advanced LVH with a history of pacemaker implantation. The finding of pronounced cardiac hypertrophy resulted in the initial clinical diagnosis of HCM in all subjects, resulting in Fabry-specific therapy (enzyme replacement therapy) being withheld for >20 years after initial presentation in some subjects. Subject No. 11 attended our center as an index subject after finding out that her deceased grandfather had tested positive for Fabry disease.
Cardiac Organ Involvement
Standard 12-lead ECG revealed sinus rhythm in 23 (88%) subjects, T-wave inversions in 15 (58%), and a pacemakertriggered rhythm in 3 (12%; subject Nos. 15, 17, and 24; Figure 1 ). Two subjects exhibited paroxysmal ventricular tachycardia in Holter monitoring ECG. The majority of subjects (92%) reported good exercise capacity according to New York Heart Association class I-II, but only 6/25 (24%) reached their age-predicted heart rates in cardiac stress testing, with maximal heart rates of 143±25 (100-191) beats per minute and maximum performance of 139±41 (75-250) Watts. Six of the 26 subjects (23%) were already in need of cardiac device therapy (2 pacemakers and 4 implantable cardioverter-defibrillators) at first presentation.
Cardiospecific biomarkers ranged from physiological to highly pathological levels: NT-proBNP was 207 (IQR, 69-955) pg/mL and hs-TnT <5 (range, <5 to 162) pg/mL in 9/22 measurements. Subjects aged >50 years (n=15) had significantly higher levels of NT-proBNP (median 680; IQR, 267-1623 pg/mL) than those aged ≤50 years (n=11; median, 69; IQR, 18-136 pg/mL; P<0.001; Figure 3 ). In addition, hsTnT levels were <5 pg/mL in 8/10 (80%) subjects aged ≤50 years (range, <5 to 7.6 pg/mL) but significantly elevated in subjects aged >50 years (median, 26.6; IQR, 16.5-50.8 pg/ mL; P<0.001). Multiple linear correlation estimation after controlling for family relatedness showed that natural logtransformed NT-proBNP (r=0.793, R²=0.629, P<0.001) and hs-TNT (r=0.677, R²=0.459, P=0.033) strongly positively correlated with age. Standard 2-dimensional echocardiography revealed preserved LV ejection fraction in most subjects (61±7% [47%-77%]); interventricular septal thickness was 12±4 (7-23) mm, and LV posterior wall thickness was 11±4 (7-21) mm (Table I in 
N215S Cardiomyopathy
Late gadolinium enhancement was reported in 18/26 (69%) subjects as an indicator of cardiac replacement fibrosis. Histological sections of EMB tissue revealed marked vacuolization of myocytes, representing centrally foamy material, and fibrosis proceeding with age ( Figure 1E and 1F) . Ultrastructurally, heart muscle cells appeared to be filled with single membrane-bound vacuoles (ie, lysosomes) containing electron-dense concentric lamellar inclusions ( Figure 1G ) as described previously. 
Extracardiac Organ Involvement
Untypical for classical Fabry phenotypes 15, 30 and despite relatively high age, none of the subjects were in need of renal replacement therapy, such as hemodialysis or kidney transplantation. The measured glomerular filtration rate (102±23 mL/min; median, 106; IQR, 84-113 Diethylene-TriaminePentaacetic Acid clearance) and serum creatinine (0.87±0.20 mg/dL; median, 0.80; IQR, 0.70-1.01) were within normal ranges. However, 2 subjects (No. 14: serum creatinine 1.20 mg/dL, measured glomerular filtration rate 81 mL/min, UACR 1330 mg/g creatinine; No. 24: serum creatinine 1.40 mg/ dL, measured glomerular filtration rate 55 mL/min, UACR 1740 mg/g creatinine) developed pathological albuminuria, as demonstrated in urine samples, and were classified as having clinically relevant chronic kidney disease. Despite comprehensive chart reviews, no other underlying kidney disease was identified as the origin of proteinuria. In consideration of the electron microscopy results ( Figure I in the Data Supplement) revealing characteristic myelin-like lipid accumulation, mainly in podocytes, and partly regular, partly effaced foot processes (n=6, subject Nos. 9, 12, 14, 18, 21, and 24), Fabry disease was assumed the most likely cause of proteinuria.
Neurological examination was normal in all subjects seen at the Department of Neurology. One male subject reported episodic pain of unknown pathogenesis at his trunk, but no typical Fabry-associated pain, such as pain attacks, evoked pain, pain crises, or permanent pain, 31 was described by any subject. Conduction studies of the right sural nerve were normal in all cases (median sensory action potential amplitude 24 μV, range 7-49 μV; median nerve conduction velocity 46 Long-term survival and prognosis in subjects with the N215S genotype. All subjects either genetically proven as having the specific N215S α-galactosidase A genotype or affected by the rules of genetic inheritance were analyzed for long-term survival. A, Survival curve for both sex (n=54), demonstrating a mean age of 74 years (70 years in males versus 77 years in females). However, several subjects died at particularly young age, leading to a cumulative survival >60 years of <60% in males. The presumable reasons for death (7 females and 6 males) were mainly reported to be cardiac (6/13, 46%), noncardiac (3/13, 23%), and unknown (4/13, 31%). B, Time of death and age of living subjects (n=54). C-H, Multiple linear regression studies (n=26) reveal an age-dependent progression of cardiac organ involvement. NT-proBNP level (G) strongly correlated with age (r=0.793, R²=0.629, P<0.001). Even though renal function decreased with age (r=−0.759, R²=0.577, P=0.007; H), an age-dependent physiological loss of glomerular filtration rate has to be considered. DTPA indicates Diethylene-Triamine-Pentaacetic Acid; GLS, global longitudinal strain; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; and NT-proBNP, N-terminal pro-brain natriuretic peptide. N215S Cardiomyopathy m/s, range 12-55 m/s). Quantitative sensory testing at the dorsal foot revealed impaired thermal perception thresholds, suggesting small nerve fiber dysfunction in 9 subjects (Table III in the Data Supplement) compared with published normative values. 27 Sixteen subjects agreed to skin punch biopsy ( Figure IIA in the Data Supplement). Intraepidermal nerve fiber density at the lower leg was reduced in 13 subjects with a median distal intraepidermal nerve fiber density of 3 (0.5-9) fibers/mm (reference, 9±3 fibers/mm). Normal values were obtained at the back except in 2 male subjects with a median of 22 fibers/mm (reference, 22±8 fibers/mm). No subject had a history of transitory ischemic attacks or cerebral stroke. Fourteen subjects underwent brain MRI, 3 presenting with unspecific white matter lesions (Fazekas score 1). One 74-year-old woman had several white matter lesions (Fazekas score 3) that could not be differentiated from age-dependent microangiopathy ( Figure IIB in the Data Supplement).
Sweating capacities were not impaired. Fabry-typical angiokeratoma and cornea verticillata were found in only 1 subject. Four subjects reported frequent diarrhea, 7 recurrent vertigo, and 5 episodes of tinnitus. Fourteen subjects had a vitamin D deficiency. With regard to epidemiologically common comorbidities, subjects were only mildly affected by hypertension (n=6), coronary artery disease (n=0), and diabetes mellitus (n=0).
Health-Related Quality of Life
The physical component summary score of the SF-36 was 47±12 (20-59) and the mental component summary score 49±11 (21-63), indicating pathologically reduced healthrelated quality of life (Table IV in the Data Supplement).
Disease Progression and Long-Term Outcome
Fourteen subjects underwent comprehensive clinical followup after ≥1 year (58±49 months) and were compared with an age-and sex-matched control group consisting of subjects with classical Fabry phenotypes (Tables 2 and 3 Follow-up observations revealed that a clinically relevant portion of subjects was in need of cardiac device therapy, leading to implantable cardioverter-defibrillator implantation in 5/26 (19%) subjects. As shown in Figure V in the Data Supplement, subjects with the N215S genotype had a similar course of fibrotic progression as reported in the literature. Though follow-up investigations showed no relevant progression of neurological or kidney disease in subjects with the N215S genotype, subjects with classical Fabry phenotypes had a burden of highly relevant multisystem organ complications, including a need for renal replacement therapy. Although cardiac organ involvement seems to be dominant in those with the N215S genotype, the need for cardiac device therapy was similar in both groups. Health-related quality of life was reduced in both groups, with a tendency of worse quality of life in classical Fabry disease.
Discussion
As a progressive multisystemic disorder, organ manifestations and symptoms may vary greatly in Fabry disease, depending on individual modifying factors such as the individual's genotype, age, and sex. The differences are anticipated to be caused by, but apparently not linearly correlated with, the accumulation of Gb3 in lysosome-carrying tissues. 10 Historically, involvement of the kidneys, peripheral nerves, and brain was described as prior-ranking pathologies, but increasing evidence indicates clinically relevant cardiac organ involvement associated with a significant burden of life-threatening ventricular tachyarrhythmia events. 32, 33 The results of the current study indicate that cardiac organ involvement is not just one of many factors in a typical multisystem Fabry phenotype, but the presence of N215S induces a specific cardiac variant of Fabry disease. This study has important implications for the diagnosis and monitoring of patients affected by cardiac variants of Fabry disease and aims to support the development of new treatment guidelines. Furthermore, the results highlight the difficulties and diagnostic pitfalls in approaching cardiac hypertrophy of unknown origin because many subjects were misinterpreted as having HCM even though they did not fulfill the typical morphological criteria of HCM. This highlights the importance of considering not only classical Fabry disease but also cardiac variants in the genetic differential diagnosis of unexplained cardiac hypertrophy.
The N215S Genotype Induces a Specific Cardiac Variant of Fabry Disease
The current results question the assumptions of recent preliminary studies suggesting that the N215S genotype represents a late-onset variant of Fabry disease. Though LVH and late gadolinium enhancement were documented as early as the third decade of life in several N215S-carrying subjects, most subjects did not present with any other clinically relevant organ injury or symptoms typically indicative of Fabry disease. With a lack of alternative explanations, the clinically relevant proteinuria in 2 subjects needs to be considered Fabry-associated. This assumption is in line with opinions on interindividual courses eventually influenced by disease-modifying factors that are still obscure. However, glomerular biopsy sample analyses have shown that renal accumulation of Gb3 occurs, to some degree, in N215S subjects. However, this does not lead to clinically relevant kidney dysfunction, eventually resulting in end-stage complications or a need for renal replacement therapy. In cases of accompanied renal failure, non-Fabry-related N215S Cardiomyopathy pathologies should be excluded before attributing it to Fabry nephropathy. Even though none of the analyzed N215S subjects had advanced renal impairment, chronic kidney disease may still appear in the case of further modifying factors, reflecting a second hit and inducing clinically relevant nephropathy. Comparisons with clinical parameters from subjects with GLA genotypes known to be associated with classical Fabry phenotypes showed that cardiac organ involvement and disease progression were comparable. As in classical Fabry disease, subjects with the N215S genotype had heart failure with preserved ejection fraction, whereas only a few elderly patients exhibited reduced cardiac ejection fraction. Notably, a relatively large proportion of subjects were in need of cardiac device therapy, and sudden cardiac arrest had been documented in several relatives, as well as in many subjects of the current group under investigation.
The subjects with the N215S genotype characterized in this study lacked all other Fabry-indicative clinical characteristics seen in classical Fabry phenotypes, such as nervous Data are given as mean±SD, median (IQR), or n (%). α-gal indicates α-galactosidase A enzyme; BL, baseline; eGFR, estimated glomerular filtration rate according to the Modification of Diet in Renal Disease formula; HRQoL, health-related quality of life; FUP, follow-up; hs-TnT, high-sensitive troponin T; MCSS, Mental Component Summary Score (SF-36); NA, not available; NT-proBNP, N-terminal pro-brain natriuretic peptide; NTx, history of kidney transplantation; PCSS, Physical Component Summary Score (SF-36); UACR, urinary albumin-to-creatinine ratio. Reference values: α-gal, 0.4-1.0 nmol/min per mg protein or 0.36-0.84 MU/mg; hs-TnT, <14 pg/mL; Lyso-Gb3, <0.9 ng/mL; NT-proBNP (age-dependent), <125 pg/mL; and UACR, <30 mg/g creatinine. *P<0.05 vs N215S. †P<0.05 vs BL.
system involvement, which most often presents as Fabryassociated acral pain and cerebrovascular events, chronic kidney disease, or skin manifestations such as angiokeratoma, all of which are usually perceived at a particularly young age. 10, 31, 34 This outlines the clinical challenge of morphological demarcation between the N215S cardiomyopathy and HCM as an eventually clinically similar appearing driver of LVH. 35 Recently published newborn screening studies that indicate a relevant portion of undiscovered Fabry patients in the general population strengthen this assumption. [36] [37] [38] Hsu et al 39 recently discussed the role of newborn screenings in regard of the IVS4+919G>A (IVS4) cardiac variant of Fabry disease, which is demographically and ethnically endemic in Asia. The investigators reported significant substrate accumulation in cardiomyocytes, which is known to be associated with cardiac replacement fibrosis, an independent risk factor for the occurrence of malign arrhythmia and sudden cardiac death. 33 Thus, they emphasize the importance of newborn screening studies because mild clinical appearance and lateonset patterns may significantly delay Fabry-specific therapy options, resulting in irreparable organ destruction and clinical complications. However, as not all GLA genotypes currently classified as pathogenic ultimately lead to the definite development of classical Fabry phenotypes requiring early-stage Taking into account the relatively high number of patients clinically diagnosed with HCM who tested negative for sarcomeric or myofilament-related genes, it seems reasonable to speculate that several patients demonstrating LVH of unknown origin are unreported N215S carriers. In all index subjects and many relatives in this study, cardiac hypertrophy was misinterpreted as HCM.
In addition to the reduced working capacity because of progressive heart failure and a somewhat limited life expectancy, subjects with the N215S genotype experienced a reduced quality of life, similar to that seen in classical Fabry disease, and potentially a target for causative therapy. With regard to the 2 subjects presenting with clinically relevant pathological proteinuria, additional yet unknown and non-Fabry-associated renal pathophysiology mechanisms have to be considered because no other subjects were clinically affected. However, as Fabry disease has great variability in both penetrance and expressivity, subjects that test positive for N215S should be monitored carefully in all regards of Fabry disease-associated organ involvement and complications. This highlights the need for an interdisciplinary reference center of excellence to monitor and treat all disease entities.
Pathophysiology and Demarcation Guidance in Hereditary Cardiomyopathies
The results of the current study in N215S-carrying subjects are in line with previous studies, highlighting the burden of rare diseases potentially leading to a wrong clinical diagnosis, such as HCM, and ultimately withholding disease-specific and life expectancy prolonging treatment, sometimes for decades. 8, 40, 41 Though several recent publications focused on genotype-specific characteristics in Fabry disease, 16, 42 the underlying pathophysiology is barely understood. Basic research has greatly improved understanding of the genotype-specific pathophysiology and modifying factors in HCM, 7, [43] [44] [45] but this has failed to clarify the pathophysiological mechanism of organ-specific phenotypes and genotype-dependent damage in patients with Fabry disease. One reasonable hypothesis questions the role of the genotypespecific presence and activity of tissue-specific microRNA in the modulation of definite phenotypes and the impact on therapeutic success. 46, 47 Further efforts may answer additional questions, eventually leading to genotype-specific therapy options and recommendations. The future role of newborn screening studies also remains in question but has already led to a sensitization toward Fabry disease. This may be of value because of the anticipated therapeutic benefits achieved by early-onset causative therapy. 41, 48 
Study Limitations
Parts of the investigations were performed as retrospective or anamnestic analyses. Therefore, comprehensive investigations of patients with left ventricular hypertrophy of unknown origin in a prospective multicenter study are needed, as well as studies taking into account the potential effects of causative medication, such as enzyme replacement therapy. In addition, some subjects presenting in 2015 and 2016 have not yet had follow-up investigations.
Conclusions
α-Galactosidase A genotype N215S induces a specific cardiac variant of Fabry disease but is usually not associated with clinically relevant extracardiac organ impairment or the symptoms of classical Fabry disease phenotypes. Thus, the N215S genotype may account for a significant number of unreported cases in subjects with suspected HCM who test negative for sarcomeric or myofilament-related gene mutations. Our study outlines clinical challenges in the demarcation between HCM and N215S, prompting investigation of both gene regions in respective cohorts of patients suspected of HCM. Identifying these patients has a clinical impact because disease-specific, symptom-reducing, and life-prolonging therapy options are available for Fabry disease.
